245 related articles for article (PubMed ID: 21804130)
1. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Barter PJ; Rye KA; Tardif JC; Waters DD; Boekholdt SM; Breazna A; Kastelein JJ
Circulation; 2011 Aug; 124(5):555-62. PubMed ID: 21804130
[TBL] [Abstract][Full Text] [Related]
2. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
[TBL] [Abstract][Full Text] [Related]
3. Letter by Knop regarding article, "Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial".
Knop FK
Circulation; 2012 Mar; 125(9):e428. PubMed ID: 22392871
[No Abstract] [Full Text] [Related]
4. Letter by McGuire and Aguilar regarding article, "Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial".
McGuire DK; Aguilar D
Circulation; 2012 Mar; 125(9):e427. PubMed ID: 22392870
[No Abstract] [Full Text] [Related]
5. Effect of torcetrapib on the progression of coronary atherosclerosis.
Nissen SE; Tardif JC; Nicholls SJ; Revkin JH; Shear CL; Duggan WT; Ruzyllo W; Bachinsky WB; Lasala GP; Tuzcu EM;
N Engl J Med; 2007 Mar; 356(13):1304-16. PubMed ID: 17387129
[TBL] [Abstract][Full Text] [Related]
6. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.
Bots ML; Visseren FL; Evans GW; Riley WA; Revkin JH; Tegeler CH; Shear CL; Duggan WT; Vicari RM; Grobbee DE; Kastelein JJ;
Lancet; 2007 Jul; 370(9582):153-160. PubMed ID: 17630038
[TBL] [Abstract][Full Text] [Related]
7. Effects of torcetrapib in patients at high risk for coronary events.
Barter PJ; Caulfield M; Eriksson M; Grundy SM; Kastelein JJ; Komajda M; Lopez-Sendon J; Mosca L; Tardif JC; Waters DD; Shear CL; Revkin JH; Buhr KA; Fisher MR; Tall AR; Brewer B;
N Engl J Med; 2007 Nov; 357(21):2109-22. PubMed ID: 17984165
[TBL] [Abstract][Full Text] [Related]
8. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
9. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
[TBL] [Abstract][Full Text] [Related]
10. Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Williams SA; Murthy AC; DeLisle RK; Hyde C; Malarstig A; Ostroff R; Weiss SJ; Segal MR; Ganz P
Circulation; 2018 Mar; 137(10):999-1010. PubMed ID: 28974520
[TBL] [Abstract][Full Text] [Related]
11. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
McKenney JM; Davidson MH; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
[TBL] [Abstract][Full Text] [Related]
13. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
de Haan W; de Vries-van der Weij J; van der Hoorn JW; Gautier T; van der Hoogt CC; Westerterp M; Romijn JA; Jukema JW; Havekes LM; Princen HM; Rensen PC
Circulation; 2008 May; 117(19):2515-22. PubMed ID: 18458167
[TBL] [Abstract][Full Text] [Related]
14. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
15. Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters.
Briand F; Prunet-Marcassus B; Thieblemont Q; Costard C; Muzotte E; Sordello S; Sulpice T
Atherosclerosis; 2014 Apr; 233(2):359-362. PubMed ID: 24530763
[TBL] [Abstract][Full Text] [Related]
16. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
Nicholls SJ; Tuzcu EM; Brennan DM; Tardif JC; Nissen SE
Circulation; 2008 Dec; 118(24):2506-14. PubMed ID: 19029466
[TBL] [Abstract][Full Text] [Related]
17. Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism.
Brousseau ME; Millar JS; Diffenderfer MR; Nartsupha C; Asztalos BF; Wolfe ML; Mancuso JP; Digenio AG; Rader DJ; Schaefer EJ
J Lipid Res; 2009 Jul; 50(7):1456-62. PubMed ID: 19193611
[TBL] [Abstract][Full Text] [Related]
18. Effect of atorvastatin on pancreatic Beta-cell function and insulin resistance in type 2 diabetes mellitus patients: a randomized pilot study.
Goyal A; Singh S; Tandon N; Gupta N; Gupta YK
Can J Diabetes; 2014 Dec; 38(6):466-72. PubMed ID: 24933106
[TBL] [Abstract][Full Text] [Related]
19. Relationship between atorvastatin dose and the harm caused by torcetrapib.
Barter PJ; Rye KA; Beltangady MS; Ports WC; Duggan WT; Boekholdt SM; DeMicco DA; Kastelein JJ; Shear CL
J Lipid Res; 2012 Nov; 53(11):2436-42. PubMed ID: 22941786
[TBL] [Abstract][Full Text] [Related]
20. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
Brousseau ME; Diffenderfer MR; Millar JS; Nartsupha C; Asztalos BF; Welty FK; Wolfe ML; Rudling M; Björkhem I; Angelin B; Mancuso JP; Digenio AG; Rader DJ; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1057-64. PubMed ID: 15761191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
